Core Viewpoint - OKURA HOLDINGS has announced a conditional placement agreement to issue up to 84.98 million shares at a price of HKD 0.143 per share, representing a discount of approximately 15.88% from the closing price of HKD 0.170 [1] Group 1: Placement Details - The company has appointed a placement agent to facilitate the placement to at least six subscribers [1] - If all placement shares are successfully placed, the total proceeds from the placement are expected to be HKD 12.15 million, with a net amount of approximately HKD 10.38 million after deducting commissions and other costs [1] Group 2: Use of Proceeds - The company plans to allocate approximately 50% of the net proceeds for the purchase of Japanese pachinko machines and Japanese slot machines [1] - About 30% of the net proceeds will be used for the renovation or enhancement of existing Japanese pachinko game halls and for marketing expenses [1] - The remaining approximately 20% will be allocated for general working capital of the group [1]

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies. Core Insights - The report highlights significant developments in the overseas pharmaceutical sector, including the collaboration between Insilico Medicine and Heng Tai Biopharma to develop a novel NLRP3 inhibitor for central nervous system diseases [2][6]. - The report notes that MicroPort Robotics expects a revenue growth of approximately 110%-120% year-on-year for 2025, with an adjusted net loss not exceeding 240 million yuan, representing a reduction of over 50% [5][6]. - GSK has reached a final agreement to acquire RAPT Therapeutics for approximately 2.2 billion USD, focusing on a long-acting monoclonal antibody currently in clinical trials [7][8]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biopharma have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with both companies holding 50% global rights [2][6]. - The Hong Kong Stock Exchange has approved the full circulation of 182,645,856 H shares for Fuhong Hanlin, representing about 33.61% of the company's total issued shares as of January 19 [2][6]. - The new drug application for TLX591-CDx, a radiopharmaceutical for prostate cancer diagnosis, has been accepted by the NMPA [2][6]. 2. Company Updates - MicroPort Robotics has reported over 180 commercial orders and more than 120 installations globally as of January 21 [5][6]. - Legend Biotech, a joint venture of Genscript Biotech, reported a trade sales net of approximately 555 million USD for the quarter ending December 31, 2025 [5][6]. - GSK's acquisition of RAPT Therapeutics includes a payment of 58.00 USD per share, with an expected upfront investment of 1.9 billion USD after cash adjustments [7][8]. 3. Market Performance - The Hang Seng Healthcare Index fell by 4.35%, underperforming the Hang Seng Index by 3.26 percentage points [4]. - The report indicates a strong performance in the overseas education sector, with GMV for Dongfang Zhenxuan reaching approximately 310 million yuan, a 42.8% increase week-on-week [15][16]. 4. Recommendations - The report suggests focusing on innovative drugs and the ongoing clinical progress of key pipelines from companies such as BeiGene, Innovent Biologics, and others [12]. - It also recommends monitoring the performance of educational companies like Dongfang Zhenxuan and China Oriental Education, which are expected to benefit from improved operational strategies and increased enrollment [16].

Core Viewpoint - Goldman Sachs reports that several Macau gaming stocks are set to announce their Q4 2025 earnings, with investors expected to focus on profit trends amid concerns over additional spending for the National Games in November and intense competition [1] Industry Summary - The firm anticipates a quarterly and year-on-year increase in industry EBITDA by 4% and 13% respectively, compared to a quarterly and year-on-year increase in total gaming revenue of 6% and 14%, driven by rising operating expenses and a shift towards lower-margin VIP gaming [1] Company Summaries - Galaxy Entertainment (00027) is expected to see its EBITDA rise by 28% quarter-on-quarter to $550 million, attributed to a higher VIP win rate [1] - MGM China (02282) is projected to have its EBITDA increase by 8% quarter-on-quarter to $328 million, due to a robust recovery in gaming revenue [1] - Sands China (01928) is forecasted to experience a 4% quarter-on-quarter EBITDA increase to $628 million, as retail revenue growth is offset by higher operating expenses and promotional costs [1] Future Outlook - For 2026, the firm expects overall gaming revenue to increase by 8% year-on-year and EBITDA to rise by 10%, leading to industry EBITDA and recurring free cash flow reaching $9.1 billion and $6.4 billion respectively, nearing pre-COVID levels [1] - The firm believes that the current industry valuations remain attractive and reiterates a "buy" rating for Galaxy Entertainment, MGM China, and Sands China [1]

Investment Rating - The report maintains a "Positive" outlook on the overseas pharmaceutical sector, highlighting significant developments and collaborations in the industry [1]. Core Insights - The collaboration between Insilico Medicine and Heng Tai Biologics to develop an innovative brain-penetrating NLRP3 inhibitor is a key highlight, with potential applications in treating central nervous system diseases [2][7]. - The approval of full circulation for Fuhong Hanlin's H shares is noted, which involves a significant number of shares and stakeholders [2][7]. - The report emphasizes the strong revenue growth projections for companies like MicroPort Robotics and King’s Ray Biotech, with expected revenue increases of approximately 110%-120% year-on-year for 2025 [6][10]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biologics have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with a 50% global rights share and potential milestone payments exceeding HKD 500 million [2][7]. - Fuhong Hanlin's H shares have received approval for full circulation, involving 182,645,856 shares, which represents about 33.61% of the company's total issued shares [2][7]. 2. Company Performance Updates - MicroPort Robotics anticipates a revenue increase of 110%-120% for 2025, with adjusted net losses expected to narrow by over 50% [6][10]. - King’s Ray Biotech's joint venture, Legend Biotech, is projected to generate approximately USD 555 million in trade sales for the quarter ending December 31, 2025 [6][10]. 3. Recent Developments in Overseas Pharmaceutical Companies - GSK has reached an agreement to acquire RAPT Therapeutics for approximately USD 2.2 billion, focusing on a long-acting IgE monoclonal antibody currently in clinical trials [3][8]. - Corvus has reported positive results from a Phase I trial of its ITK inhibitor for moderate to severe atopic dermatitis, showing good safety and efficacy [3][9]. - Eli Lilly's FRα ADC has received breakthrough therapy designation from the FDA for treating platinum-resistant ovarian cancer [3][9]. 4. Recommendations - The report suggests monitoring innovative drug companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and Fuhong Hanlin [13]. - It also highlights the importance of ongoing clinical progress in innovative pipelines for pharmaceutical companies transitioning towards innovation [13].

澳门励骏(01680)公布，章程及包销协议所载全部条件均已获达成，且联席包销商并未终止包销协议， 故供股于2026年1月16日(星期五)下午五时正成为无条件。于合併计算后，涉及约1.53亿股供股股份的33 份有效接纳及申请已获接纳及申请，占根据供股提呈发售约3.1亿股供股股份总数约49.49%。 供股所得款项总额约为9300万港元，净筹约8640万港元。 供股获认购不足约1.57亿股供股股份，占根据供股提呈发售约3.1亿股供股股份总数约50.51%。东亚证 券及百德能经纪(即包销协议项下的联席包销商)已根据章程所披露包销协议条款承购全部约1.57亿股未 获承购供股股份。 ...

Group 1 - The core viewpoint is that Galaxy Entertainment is expected to increase its market share in 2026, following a rise in net revenue and adjusted EBITDA in Q4 2025 [1] - In Q4 2025, Galaxy Entertainment recorded net revenue of HKD 12.2 billion, a year-on-year increase of 14%, with adjusted EBITDA also rising by 14% to HKD 3.3 billion [1] - The company anticipates a market share of approximately 20% for the full year of 2025, maintaining its position as the second-largest player in the industry [1] Group 2 - Macau's gaming revenue is projected to grow by 9.1% year-on-year to MOP 247.4 billion in 2025, with a significant increase of 13.8% in the second half of the year [2] - The upcoming longer Spring Festival holiday in 2026 is expected to boost travel demand from mainland citizens, benefiting Macau's tourism and gaming sectors [2] - Galaxy Entertainment is likely to attract more investor interest compared to competitors, due to increased brand fees and geopolitical considerations affecting peers [2] Group 3 - The current valuation of Galaxy Entertainment is at 10.6 times the 2026 EV/EBITDA, which is considered low compared to the pre-pandemic range of 10.0 to 14.0 times [3] - There is potential for further upward adjustment in valuation as the company's performance continues to improve [3]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of HKD 45.50, indicating an upside potential of 12.6% from the current price of HKD 40.42 [5][8]. Core Insights - The company recorded a net revenue of HKD 12.2 billion for Q3 2025, representing a year-on-year increase of 14%. Adjusted EBITDA also rose by 14% to HKD 3.3 billion, with a normalized net win rate leading to a 7% increase in adjusted EBITDA [1]. - The company's market share is estimated to be around 20% for the full year of 2025, maintaining its position as the second-largest player in the industry. Management indicated an increase in market share for Q4 2025, with expectations for further growth in 2026 due to the utilization of new projects opening in December 2023 [1]. - Macau's gaming revenue is projected to grow by 9.1% year-on-year to MOP 247.4 billion in 2025, with a significant increase of 13.8% in the second half of 2025. The upcoming longer Spring Festival holiday in 2026 is expected to boost travel demand from mainland citizens, benefiting the tourism sector and the company [2]. - Competitors are facing increased brand fees and geopolitical concerns, which may lead to a preference for the company among investors. MGM China announced a new brand agreement that doubles its brand fees, raising market concerns for other competitors [3]. - The company's current valuation is at 10.6 times the 2026 EV/EBITDA, which is considered low compared to the pre-pandemic range of 10.0 to 14.0 times, suggesting potential for valuation re-rating as performance improves [4]. Financial Summary - Revenue projections for the company are as follows: FY22: HKD 11.474 billion, FY23: HKD 35.684 billion, FY24: HKD 43.432 billion, FY25E: HKD 48.574 billion, FY26E: HKD 52.232 billion [5]. - EBITDA projections are: FY22: HKD (0.553) billion, FY23: HKD 9.955 billion, FY24: HKD 12.188 billion, FY25E: HKD 14.020 billion, FY26E: HKD 14.971 billion [5].

餐饮： 12月餐饮&酒店&旅游&免税&博彩 数据跟踪【东财新消费 | 社服】 酒店：#12月RevPAR增速环比有所回落。 ①正餐：海底捞/太二/呷哺/小菜园同店店效（单店月GMV，堂食，下同）同比-7%/-13%/-5%/-12%；其中海底捞翻 台率4.1次/天（#连续3个月回归4以上），同比-0.5，环比-0.1； ②快餐：肯德基/麦当劳/必胜客/塔斯汀同店店效分别-3%/-1%/-7%/-2%； ③茶咖：蜜雪/古茗/沪上阿姨/茶百道/霸王茶姬/喜茶同店店效分别+15%/+5%/+5%/-1%/-17%/+13%。 瑞幸/库迪/星巴克/幸运咖同店店效分别-3%/-2%/+1%/+17%，库迪、幸运咖及manner高速拓店。 免税：#12月海南离岛免税购物金额同比+17%，连续4个月正增（9-11月同比+3%/+13%/+27%）；人次-3%；客 单价+21%。 ①正餐：海底捞/太二/呷哺/小菜园同店店效（单店月GMV，堂食，下同）同比-7%/-13%/-5%/-12%；其中海底捞翻 台率4.1次/天（#连续3个月回归4以上），同比-0.5，环比-0.1； ②快餐：肯德基/麦当劳/必胜客/塔斯汀同店店效分别 ...

Core Insights - The Macau gaming industry is undergoing a significant transformation, marked by the closure of satellite casinos by the end of 2025 and a widespread salary increase for nearly 100,000 employees in early 2026, reflecting the industry's shift from decentralization to concentration [1][3][4] Salary Increase and Employee Impact - Six major integrated tourism and leisure companies in Macau announced bonus and salary increase plans, with a uniform raise of 500 MOP for employees earning 16,000 MOP or less, and approximately a 2% increase for those earning above that threshold, benefiting about 99% of frontline employees [2][3] - The total number of employees affected by this salary increase is close to 100,000, emphasizing the industry's commitment to team contributions and shared success [2][3] Closure of Satellite Casinos - The last satellite casino, the Landmarks Casino, will close on December 31, 2025, marking the end of an era for this model that has been part of Macau's gaming landscape for nearly 50 years [4][5] - The closure of satellite casinos, which involved around 5,600 local employees, is seen as a pivotal moment in the industry's transition towards a more concentrated operational model [4][5] Industry Transformation and Regulatory Changes - The new gaming regulations have reinforced the legal status of satellite casinos and provided a framework for their phased exit, indicating a shift towards a more regulated and concentrated gaming environment [5][6] - The closure of satellite casinos is viewed as a necessary step for the growth of integrated resorts, which have become the preferred model for tourism in Macau [5][6] Tourism Growth and Non-Gaming Investments - Macau's tourism sector achieved a record-breaking 40 million visitors in 2025, a 14.7% increase year-on-year, contributing to the overall recovery of the gaming industry [7][8] - Non-gaming investments and activities have increased significantly, with major companies hosting nearly 600 events in 2025, indicating a strategic shift towards diversifying revenue sources beyond gaming [9] Future Outlook and Key Performance Indicators - The upcoming three-year assessment period starting in 2026 will evaluate the performance of gaming companies in terms of their non-gaming investments, which are crucial for the industry's structural transformation [9] - The growth of international visitors and the focus on non-gaming elements are expected to be key indicators of the industry's success in adapting to new market demands [9]

公司目前正就该事宜寻求法律意见。然而，集团已对该等资产的账面值全额减值，故此，于本公告日 期，该等资产的账面值为零。因此，董事会认为，投资项目的近期发展将不会对公司的营运或财务表现 产生重大不利影响。 智通财经APP讯，澳门励骏(01680)发布公告，于2026年1月15日，公司获佛得角政府通知，其拟于2026 年1月16日接管该等资产。佛得角政府要求公司到场进行自愿移交。经确定该要求缺乏任何合法依据， 公司未予同意。佛得角政府不顾公司反对自愿移交，已通过进入位于佛得角Cidade da Praia Bay的投资 项目场地而接管该等资产。 ...